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Abstract:
The expression of the EphA2 tyrosine kinase receptor differs between normal and malignant
cells, with many human carcinomas presenting an overexpression of EphA2 [1]. Normal
expression of EphA2 results in tumor suppression, whereas overexpression promotes tumor
progression by ligand-independent activation of EphA2 through the phosphorylation of S897 by
Akt. However, by inducing EphA2 activation, Akt is inhibited, ultimately resulting in a decrease
in the migration and invasiveness of cancer cells [2]. Here, we designed a peptide, Roxy7, to
specifically target the transmembrane domain of EphA2 in cancer cells in a pH-dependent
manner in order to induce clustering and therefore activation. Biophysical studies suggest that at
pH 8 Roxy7 binds to the lipid membrane and, upon acidification, will insert as a transmembrane
ɑ-helix. To determine the affinity of Roxy7 for lipid bilayers, we conjugated Roxy7 with
nitrobenzoxadiole (NBD) and used an NBD binding assay to compare the fluorescence intensity
of Roxy7 to the negative control peptide Roxy8 as both lipid concentration and pH varied. Our
results indicate that Roxy7 partitions to lipid bilayers with greater affinity at acidic pH. Since the
extracellular pH of tumors is known to be more acidic than healthy cells, our results suggest that
Roxy7 is capable of targeting tumors and binding to the membrane of cancer cells.

Introduction:
Both normal and oncogenic development is partly regulated by Erythropoietin-producing
hepatocellular (Eph) receptor tyrosine kinases and their associated ligands, called ephrins [1].
One member of this receptor family is EphA2, with its associated ligand ephrin-A1. EphA2
expression differs between normal and malignant cells, with many human carcinomas presenting
with an overexpression of EphA2. In epithelial cells with regular levels of EphA2 expression,
ligand-dependent activation of EphA2 leads to a reduction in the amount of extracellular matrix
attachments, a decrease in cell migration, and inhibition of malignant growth through the
inactivation of the Ras/ERK, RSK, and Akt pathways [2,3,4]. On the other hand, cancer cells
with overexpression of EphA2 are often accompanied by the loss of ephrin-A1, and thus do not
participate in this stable ligand-binding. Instead, these cancer cells can acquire ligandindependent pro-oncogenic functions by activating EphA2 through the phosphorylation of S897
by Akt or RSK [2,4].

We designed a peptide, Roxy7, to specifically target the transmembrane domain of
EphA2 in cancer cells in a pH-dependent manner in order to induce clustering and activate
ligand-dependent type signaling in EphA2. However, before we could move forward with the
EphA2 effects, we needed to know if Roxy7 could target and bind to cancer cells. In this study, I
sought to determine the insertion and the binding affinity of Roxy7. Circular dichroism was used
to monitor insertion of Roxy7 into a lipid bilayer, and fluorimetry was employed to determine
the binding affinity of Roxy7 through the use of an NBD binding assay. Studies suggest that at
pH 8 Roxy7 binds to the lipid membrane and, upon acidification, inserts as a transmembrane ɑhelix. Additionally, the results indicate that Roxy7 partitions to lipid bilayers with greater
affinity at acidic pH. Since the extracellular pH of tumors is known to be more acidic than
healthy cells, our results suggest that Roxy7 is capable of binding to the membrane of cancer
cells.
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Figure1. The pH responsive insertion of the
peptide as the environment acidifies.
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Figure 2. The re-activation of ligand-dependent signaling
inhibits Akt and ligand-independent signaling.

Materials and Methods:
Circular Dichroism
Peptide stocks were made for both Roxy7 and Roxy8. Dried POPC lipid was resuspended
in a 1 mM sodium phosphate buffer at neutral pH, and extruded using a 100 nm filter to make
100 nm large unimellar vesicles. A master mix was made containing the lipid, the peptide, and
the 1 mM buffer at a neutral pH, and allowed to incubate for one hour. A lipid blank, a peptide
blank, and a buffer blank were prepared in addition to the four samples (two at pH 4, two at pH

8). Samples consisted of the Master Mix, a 10 mM (Roxy8) or a 100mM buffer (Roxy7) at either
pH4 or pH8, and water. Circular dichroism was performed at room temperature across the
wavelength range from 260nm-190nm. Data was normalized to give ellipticity, and ellipticiy was
plotted against wavelength to determine the secondary structure of the peptide.

Fluorimetry
Roxy7 and Roxy8 were conjugated with NBD at the N terminal by using NBD-X
succimidyl ester, which specifically targets primary amines, and then lyophilized into aliquots. A
dried POPC sample was resuspended in a 10 mM buffer at the pH for that experiment in order to
make a 1mM POPC solution. The lipid solution was extruded using a 100 nm filter to make 100
nm large unimellar vesicles. The dried Roxy7-NBD or Roxy8-NBD was resuspended in 400
microliters of MiliQ water and quantified using a spectrophotometer and the Beer-Lambert Law.
The same buffer used for the lipid resuspension was used to prepare the samples. The
final volume for the sample was 130 microliters. The final concentration of peptide in the sample
was 1 micromolar. The lipid concentration in the sample ranged from 0 to 800 micromolar. Lipid
blanks were prepared to match the lipid concentration in each sample. Fluorimetry was used to
measure the fluorescence intensity across a 60 nm range (520nm-580nm). The maximum
fluorescence intensity at 540nm for each sample was plotted versus the varying lipid
concentration. The subsequent binding curve was fitted to the following equation, which gave
the partition coefficient:
F0 + Fmax * [

𝐾𝑝×𝑥
55.3+𝐾𝑝×𝑥

]

Results:
Circular dichroism of Roxy7 suggests the formation of an ɑ-helix at acidic pH (Figure 3).
This secondary structure is denoted by the negative minima at 208nm and 222nm. The similar
structure of the peptide at both pH 8 and in buffer suggests that at a basic pH the peptide is in
solution.
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Figure 1. Circular dichroism of Roxy7 in POPC vesicles shows ɑ-helix formation in acidic conditions, denoted by the minima at
208 nm and 222 nm.

NBD binding assays across multiple pH values for both Roxy7 and its negative control,
Roxy8, suggest greater binding for Roxy7 at acidic pH. Binding was assessed by comparing
partition coefficient (Kp) values (Figure 4). In addition, the maximum fluorescent intensity of the
pH 5 and pH 7 experiments were averaged, normalized, and then plotted against lipid
concentration to further view the tighter binding of Roxy7 at lower pHs (Figure 5).
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Figure 2.Comparison of partition coefficient (Kp) values for Roxy7 and Roxy8 at varying pH values. Suggests
increased binding of Roxy 7 at lower pH values. Asterisk denotes n=1.
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Figure 3.Overlay of average Roxy7-NBD binding assay at pH 5 (red) and pH 7 (blue) demonstrating tighter binding at lower pH.

Discussion and Conclusions:
The circular dichroism of Roxy7 suggests that the interaction of the peptide with POPC
lipid vesicles is controlled by pH. This pH-responsive property suggests that the peptide could be
used to target cancer cells because it would remain in solution until it reached an acidic
environment. The CD spectra further suggests that in an acidic environment, Roxy7 would insert
into a membrane as a transmembrane ɑ-helix, and thus could interact with and activate
overexpressed EphA2.
In addition to the CD spectra of Roxy7, the NBD binding assays suggest that acidic
environments also allow for tighter binding of the peptide to the membrane. The binding was
assessed by the Kp value, which measures the partitioning of the peptide. If the peptide partitions
more toward the lipid, the Kp value is high. If the peptide partitions more toward the solution,
the Kp value is low. Figure 4 suggests that as the pH of the environment acidifies, the Kp value
of Roxy7 increases, meaning the peptide is favoring the lipid membrane more than the solution
and thus has tighter binding. Additionally, the binding curves represented in Figure 5 further
collaborate these findings. The slope of the curve of the pH 5 experiments is steeper than that of
the pH 7 experiments, illustrating a tighter binding at the lower pH.

Together, these experiments suggest that Roxy7 can be used to target cancer cell
membranes, and that Roxy7 has a potential pH delivery property that can be useful for targeting
tumor cells.
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